HRMY250117P30000
- 0.35
- 0.000.00%
Harmony Biosciences Newsroom
H.C. Wainwright Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $75
Harmony Biosciences Analyst Ratings
H.C. Wainwright Initiates Harmony Biosciences(HRMY.US) With Buy Rating, Announces Target Price $75
Harmony Biosciences Initiated With a Buy at H.C. Wainwright
Piper Sandler Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $48
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating
Harmony Biosciences Is Maintained at Overweight by Cantor Fitzgerald
Goldman Sachs Maintains Harmony Biosciences(HRMY.US) With Sell Rating, Maintains Target Price $28
Cantor Fitzgerald Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $58
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating
Oppenheimer Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $59
Harmony Biosciences Analyst Ratings
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $52
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating
Goldman Sachs Maintains Harmony Biosciences(HRMY.US) With Sell Rating, Announces Target Price $28
Raymond James Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $40
Harmony Biosciences Analyst Ratings
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Announces Target Price $52
Oppenheimer Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $56
A Quick Look at Today's Ratings for Harmony Biosciences(HRMY.US), With a Forecast Between $44 to $56